Education
About Us
Working with TipRanks
Follow Us
Renovaro Biosciences (RENB)
NASDAQ:RENB
Total Valuation
Renovaro Biosciences has a market cap or net worth of $75.19M. The enterprise value is $64.46M.
Market Cap$75.19M
Enterprise Value$64.46M
Share Statistics
Renovaro Biosciences has 230,928,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding230,928,970
Owned by Insiders24.50%
Owned by Institutions0.05%
Financial Efficiency
Renovaro Biosciences’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -60.13%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-60.13%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-3.23M
Employee Count25
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.62
Price to Fair Value1.14
Price to FCF<0.01
Price to Operating Cash Flow<0.01
PEG Ratio-0.03
Income Statement
In the last 12 months, Renovaro Biosciences had revenue of 0.00 and earned -80.65M in profits. Earnings per share was -0.84.
Revenue0.00
Gross Profit-121.86K
Operating Income-81.64M
Pretax Income-80.65M
Net Income-80.65M
EBITDA-81.52M
Earnings Per Share (EPS)-0.84
Cash Flow
In the last 12 months, operating cash flow was 11.77T and capital expenditures 29.77B, giving a free cash flow of 11.80T billion.
Operating Cash Flow11.77T
Free Cash Flow11.80T
Free Cash Flow per Share51.12K
Dividends & Yields
Renovaro Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.68
52-Week Price Change-73.73%
50-Day Moving Average0.32
200-Day Moving Average0.63
Relative Strength Index (RSI)48.54
Average Volume (3m)2.93M
Important Dates
Renovaro Biosciences upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Renovaro Biosciences as a current ratio of 0.07, with Debt / Equity ratio of 7.96%
Current Ratio0.07
Quick Ratio0.07
Debt to Market Cap0.02
Net Debt to EBITDA-0.04
Interest Coverage Ratio-80.73
Taxes
In the past 12 months, Renovaro Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Renovaro Biosciences EV to EBITDA ratio is -1.89, with an EV/FCF ratio of -13.92.
EV to Sales0.00
EV to EBITDA-1.89
EV to Free Cash Flow-13.92
EV to Operating Cash Flow-14.01
Balance Sheet
Renovaro Biosciences has $923.00K in cash and marketable securities with $7.03M in debt, giving a net cash position of $6.11M billion.
Cash & Marketable Securities$923.00K
Total Debt$7.03M
Net Cash$6.11M
Net Cash Per Share$0.03
Tangible Book Value Per Share-$0.28
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Renovaro Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―